ZYUS Life Sciences (TSXV:ZYUS) Piotroski F-Score: 2 (As of Jul. 21, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:ZYUS ZYUS Life Sciences Corp TSXV:ZYUS
16 GF Score
Price C$0.50
! 6 Warning Signs
View Full Analysis

What is ZYUS Life Sciences Piotroski F-Score?

ZYUS Life Sciences TSXV:ZYUS 16 Piotroski F-Score is 2 as of Jul. 21, 2026, which is at its 10-year median of 2.00. GuruFocus rates TSXV:ZYUS with a GF Score™ of 16/100. The stock has 6 warning signs investors should review. Among 979 Drug Manufacturers companies, ZYUS Life Sciences ranks worse than 91.42% on this metric.

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

ZYUS Life Sciences has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for ZYUS Life Sciences's Piotroski F-Score or its related term are showing as below:

TSXV:ZYUS' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 2   Max: 2
Current: 2

During the past 5 years, the highest Piotroski F-Score of ZYUS Life Sciences was 2. The lowest was 2. And the median was 2.

ZYUS Life Sciences  (TSXV:ZYUS) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


ZYUS Life Sciences Piotroski F-Score Related Terms


ZYUS Life Sciences Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for ZYUS Life Sciences's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ZYUS Life Sciences Piotroski F-Score Chart

ZYUS Life Sciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
N/A N/A N/A 2.00 0.00

ZYUS Life Sciences Quarterly Data
Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 2.00 2.00 0.00 0.00

TSXV:ZYUS vs ZTS, UTHR: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, ZYUS Life Sciences's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ZYUS Life Sciences Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ZYUS Life Sciences's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where ZYUS Life Sciences's Piotroski F-Score falls into.


TSXV:ZYUS
16GF Score
ZYUS Life Sciences Corp TSXV:ZYUS
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -4.424 + -3.624 + -9.724 + -3.062 = C$-20.83 Mil.
Cash Flow from Operations was -1.951 + -2.521 + -1.927 + -1.391 = C$-7.79 Mil.
Revenue was 0.12 + 0.105 + 0.066 + 0.122 = C$0.41 Mil.
Gross Profit was 0.069 + -0.004 + -0.075 + 0.055 = C$0.05 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(12.49 + 11.782 + 10.849 + 5.076 + 4.672) / 5 = C$8.9738 Mil.
Total Assets at the begining of this year (Mar25) was C$12.49 Mil.
Long-Term Debt & Capital Lease Obligation was C$12.22 Mil.
Total Current Assets was C$0.91 Mil.
Total Current Liabilities was C$16.40 Mil.
Net Income was -4.812 + -3.918 + -21.737 + -3.959 = C$-34.43 Mil.

Revenue was 0.118 + 0.123 + 0.126 + 0.114 = C$0.48 Mil.
Gross Profit was 0.064 + 0.071 + -0.064 + 0.06 = C$0.13 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(38.221 + 35.787 + 33.979 + 14.673 + 12.49) / 5 = C$27.03 Mil.
Total Assets at the begining of last year (Mar24) was C$38.22 Mil.
Long-Term Debt & Capital Lease Obligation was C$7.60 Mil.
Total Current Assets was C$1.90 Mil.
Total Current Liabilities was C$12.36 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

ZYUS Life Sciences's current Net Income (TTM) was -20.83. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

ZYUS Life Sciences's current Cash Flow from Operations (TTM) was -7.79. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-20.834/12.49
=-1.66805444

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-34.426/38.221
=-0.90070903

ZYUS Life Sciences's return on assets of this year was -1.66805444. ZYUS Life Sciences's return on assets of last year was -0.90070903. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

ZYUS Life Sciences's current Net Income (TTM) was -20.83. ZYUS Life Sciences's current Cash Flow from Operations (TTM) was -7.79. ==> -7.79 > -20.83 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=12.222/8.9738
=1.36196483

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=7.595/27.03
=0.28098409

ZYUS Life Sciences's gearing of this year was 1.36196483. ZYUS Life Sciences's gearing of last year was 0.28098409. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=0.912/16.401
=0.05560637

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=1.898/12.362
=0.15353503

ZYUS Life Sciences's current ratio of this year was 0.05560637. ZYUS Life Sciences's current ratio of last year was 0.15353503. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

ZYUS Life Sciences's number of shares in issue this year was 80.127. ZYUS Life Sciences's number of shares in issue last year was 74.358. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0.045/0.413
=0.10895884

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0.131/0.481
=0.27234927

ZYUS Life Sciences's gross margin of this year was 0.10895884. ZYUS Life Sciences's gross margin of last year was 0.27234927. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=0.413/12.49
=0.03306645

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=0.481/38.221
=0.0125847

ZYUS Life Sciences's asset turnover of this year was 0.03306645. ZYUS Life Sciences's asset turnover of last year was 0.0125847. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+0+0+0+1
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

ZYUS Life Sciences has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 2 mean?
ZYUS Life Sciences (TSXV:ZYUS) has a Piotroski F-Score of 2 as of Jul. 21, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on ZYUS Life Sciences and its competitors. This is near median its historical median of 2.00. Over the past decade, ZYUS Life Sciences' Piotroski F-Score has ranged from 2.00 to 2.00. According to the industry distribution chart, ZYUS Life Sciences ranks #895 out of 979 companies in the Drug Manufacturers industry, placing it in the top 91.4%.
Is ZYUS Life Sciences' Piotroski F-Score too high?
ZYUS Life Sciences' current Piotroski F-Score of 2 is near median its 10-year median of 2.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 2.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. ZYUS Life Sciences' value of 2 is 60% below this industry median. Based on the distribution chart, ZYUS Life Sciences ranks #895 out of 979 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, ZYUS Life Sciences has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does ZYUS Life Sciences' Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ZYUS Life Sciences ranks #895 out of 979 companies for Piotroski F-Score. This places ZYUS Life Sciences in the lower half of its industry. The industry median Piotroski F-Score is 5.00. ZYUS Life Sciences' value of 2 is 60% below this benchmark. Historically, ZYUS Life Sciences' own Piotroski F-Score has ranged from 2.00 to 2.00 over the past decade. While the company's 10-year median is 2.00 vs. the industry median of 5.00, ZYUS Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 979 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ZYUS Life Sciences's current Piotroski F-Score of 2 is 60% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on ZYUS Life Sciences and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ZYUS Life Sciences's current Piotroski F-Score is 2, which is near median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ZYUS Life Sciences stock overvalued right now?
ZYUS Life Sciences (TSXV:ZYUS) has a current Piotroski F-Score of 2. The current Piotroski F-Score is 2, which is near median its 10-year median of 2.00 and 60% below the Drug Manufacturers industry median of 5.00. ZYUS Life Sciences' overall GF Score™ is 16/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For ZYUS Life Sciences (TSXV:ZYUS), the current Piotroski F-Score is 2 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ZYUS Life Sciences Business Description

Other Exchanges ZLSCF:USA
Address 407 Downey Road, Unit 204, Saskatoon, SK, CAN, S7N 4L8
ZYUS Life Sciences Corp is primarily engaged in the world-wide development and commercialization of cannabinoid-based therapeutics and product candidates. It is a licensed producer and distributor of medical cannabis for both medical and adult recreational access in Canada. The company has one reportable segment: Bio-pharmaceutical Products (including medical cannabis derivatives). Geographically, it operates in Canada; United States; Australia; and European Union.
16GF Score

Get the complete analysis for TSXV:ZYUS

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.50
Price